Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

Completed · Phase 3

Conditions studied: Major Depressive Disorder, Anxiety

In brief

The purpose of this study is to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety symptoms, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) response.

Key facts

Study ID

NCT02013531

Run by

Otsuka Pharmaceutical Development & Commercialization, Inc.

People needed

37

Starts

2013-11-01

Expected to finish

2014-06-01

Last updated by the study team

2016-03-29

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Tuscon, Arizona, United States
• Study site — Garden Grove, California, United States
• Study site — Oceanside, California, United States
• Study site — Temecula, California, United States
• Study site — Gainesville, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Lafayette, Indiana, United States
• Study site — Baltimore, Maryland, United States
• Study site — Boston, Massachusetts, United States
• Study site — Haverhill, Massachusetts, United States
• Study site — Rochester Hills, Michigan, United States
• Study site — New York, New York, United States
• Study site — Staten Island, New York, United States
• Study site — Salem, Oregon, United States
• Study site — Allentown, Pennsylvania, United States
• Study site — Arlington, Texas, United States
• Study site — Austin, Texas, United States
• Study site — Woodstock, Vermont, United States
• Study site — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.